<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Protein Kinase Inhibitors: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i1087.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i1087.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i1087.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i500.htm">Cytotoxics</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i1103.htm" title="Previous: Trabectedin">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i1186.htm" title="Next: Pazopanib">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i1087">Protein Kinase Inhibitors</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Protein Kinase Inhibitors</b>
          has no specific interaction information.
        </p><p>Protein Kinase Inhibitors belongs to <b>Cytotoxics</b>
          and will have the following interactions:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i364.htm">Clozapine</a></td><td class="cBV"><b>avoid concomitant use of  cytotoxics with clozapine (increased risk of agranulocytosis)</b></td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr></tbody></table><p><b>Pazopanib</b> belongs to
      <b>Protein Kinase Inhibitors</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>














<tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with atazanavir </b></td><td></td></tr><tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  pazopanib advised by manufacturer of boceprevir </b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with clarithromycin </b></td><td></td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with grapefruit juice </b></td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with indinavir </b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with itraconazole </b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with ketoconazole </b></td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td>plasma concentration of  pazopanib increased by lapatinib </td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with nelfinavir </b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with rifampicin </b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with ritonavir </b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with saquinavir </b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with telithromycin </b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>manufacturer of  pazopanib advises avoid concomitant use with voriconazole </b></td><td></td></tr></tbody></table><p><b>Gefitinib</b> belongs to
      <b>Protein Kinase Inhibitors</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>









<tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  gefitinib advised by manufacturer of boceprevir </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td>manufacturer of  gefitinib advises avoid concomitant use with carbamazepine </td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td>plasma concentration of  gefitinib increased by itraconazole </td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>manufacturer of  gefitinib advises avoid concomitant use with phenobarbital </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>manufacturer of  gefitinib advises avoid concomitant use with phenytoin </td><td></td></tr><tr><td><a href="41001i747.htm">Ranitidine</a></td><td class="cBV"><b>plasma concentration of  gefitinib reduced by ranitidine </b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  gefitinib reduced by rifampicin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td>manufacturer of  gefitinib advises avoid concomitant use with St John's wort </td><td></td></tr><tr><td><a href="41001i222.htm">Warfarin</a></td><td class="cBV"><b> gefitinib possibly enhances anticoagulant effect of warfarin </b></td><td></td></tr></tbody></table><p><b>Everolimus</b> belongs to
      <b>Protein Kinase Inhibitors</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


















<tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>plasma concentration of  everolimus possibly increased by atazanavir—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b>plasma concentration of  everolimus increased by ciclosporin </b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>plasma concentration of  everolimus possibly increased by clarithromycin—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td class="cBV"><b>plasma concentration of  everolimus possibly increased by darunavir—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>plasma concentration of  everolimus increased by erythromycin </b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td>manufacturer of  everolimus advises avoid concomitant use with grapefruit juice </td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>plasma concentration of  everolimus possibly increased by indinavir—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>plasma concentration of  everolimus possibly increased by itraconazole—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>plasma concentration of  everolimus increased by ketoconazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>plasma concentration of  everolimus possibly increased by nelfinavir—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td class="cBV"><b>plasma concentration of  everolimus possibly increased by posaconazole—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  everolimus reduced by rifampicin </b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  everolimus possibly increased by ritonavir—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>plasma concentration of  everolimus possibly increased by saquinavir—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td>plasma concentration of  everolimus possibly reduced by St John's wort—manufacturer of everolimus advises avoid concomitant use</td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>plasma concentration of  everolimus possibly increased by telithromycin—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td class="cBV"><b>plasma concentration of both drugs may increase when  everolimus given with verapamil </b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>plasma concentration of  everolimus possibly increased by voriconazole—manufacturer of everolimus advises avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Temsirolimus</b> belongs to
      <b>Protein Kinase Inhibitors</b>
          and has the following interaction information:
        </p><div>The main active metabolite of temsirolimus is sirolimus—<i>see also</i> interactions of sirolimus and consult product literature</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>plasma concentration of active metabolite of  temsirolimus increased by ketoconazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of active metabolite of  temsirolimus reduced by rifampicin—avoid concomitant use</b></td><td></td></tr></tbody></table><p><b>Lapatinib</b> belongs to
      <b>Protein Kinase Inhibitors</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






















<tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  lapatinib advised by manufacturer of boceprevir </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>plasma concentration of  lapatinib reduced by carbamazepine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i516.htm">Docetaxel</a></td><td>possible increased risk of neutropenia when  lapatinib given with docetaxel </td><td></td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with grapefruit juice </b></td><td></td></tr><tr><td><a href="41001i743.htm">Histamine H<sub>2</sub>-antagonists</a></td><td>absorption of  lapatinib possibly reduced by histamine H<sub>2</sub>-antagonists </td><td></td></tr><tr><td><a href="41001i1006.htm">Irinotecan</a></td><td class="cBV"><b> lapatinib increases plasma concentration of active metabolite of irinotecan—consider reducing dose of irinotecan</b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with itraconazole </b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>plasma concentration of  lapatinib increased by ketoconazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i517.htm">Paclitaxel</a></td><td class="cBV"><b>increased risk of neutropenia when  lapatinib given with paclitaxel </b></td><td></td></tr><tr><td><a href="41001i1186.htm">Pazopanib</a></td><td> lapatinib increases plasma concentration of pazopanib </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with phenytoin </b></td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with pimozide </b></td><td></td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with posaconazole </b></td><td></td></tr><tr><td><a href="41001i751.htm">Proton Pump Inhibitors</a></td><td>absorption of  lapatinib possibly reduced by proton pump inhibitors </td><td></td></tr><tr><td><a href="41001i855.htm">Repaglinide</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with repaglinide </b></td><td></td></tr><tr><td><a href="41001i200.htm">Rifabutin</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with rifabutin </b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with rifampicin </b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with ritonavir </b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with saquinavir </b></td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with St John's wort </b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with telithromycin </b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>manufacturer of  lapatinib advises avoid concomitant use with voriconazole </b></td><td></td></tr></tbody></table><p><b>Nilotinib</b> belongs to
      <b>Protein Kinase Inhibitors</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>










<tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  nilotinib advised by manufacturer of boceprevir </b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>manufacturer of  nilotinib advises avoid concomitant use with clarithromycin </b></td><td></td></tr><tr><td><a href="41001i829.htm">Grapefruit Juice</a></td><td class="cBV"><b>manufacturer of  nilotinib advises avoid concomitant use with grapefruit juice </b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b>manufacturer of  nilotinib advises avoid concomitant use with itraconazole </b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b>plasma concentration of  nilotinib increased by ketoconazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i421.htm">Midazolam</a></td><td> nilotinib increases plasma concentration of midazolam </td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  nilotinib reduced by rifampicin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>manufacturer of  nilotinib advises avoid concomitant use with ritonavir </b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b>manufacturer of  nilotinib advises avoid concomitant use with telithromycin </b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>manufacturer of  nilotinib advises avoid concomitant use with voriconazole </b></td><td></td></tr></tbody></table><p><b>Sunitinib</b> belongs to
      <b>Protein Kinase Inhibitors</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



<tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  sunitinib advised by manufacturer of boceprevir </b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td>metabolism of  sunitinib inhibited by ketoconazole (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  sunitinib accelerated by rifampicin (reduced plasma concentration)</td><td></td></tr></tbody></table><p><b>Sorafenib</b> belongs to
      <b>Protein Kinase Inhibitors</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>







<tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  sorafenib advised by manufacturer of boceprevir </b></td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> sorafenib possibly enhances anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i516.htm">Docetaxel</a></td><td> sorafenib increases plasma concentration of docetaxel </td><td></td></tr><tr><td><a href="41001i506.htm">Doxorubicin</a></td><td> sorafenib possibly increases plasma concentration of doxorubicin </td><td></td></tr><tr><td><a href="41001i1006.htm">Irinotecan</a></td><td> sorafenib possibly increases plasma concentration of irinotecan </td><td></td></tr><tr><td><a href="41001i133.htm">Neomycin</a></td><td>bioavailability of  sorafenib reduced by neomycin </td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>plasma concentration of  sorafenib reduced by rifampicin </td><td></td></tr></tbody></table><p><b>Imatinib</b> belongs to
      <b>Protein Kinase Inhibitors</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>












<tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  imatinib advised by manufacturer of boceprevir </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>plasma concentration of  imatinib reduced by carbamazepine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td> imatinib possibly increases plasma concentration of ciclosporin </td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td>plasma concentration of  imatinib increased by ketoconazole </td><td></td></tr><tr><td><a href="41001i738.htm">Levothyroxine</a></td><td> imatinib possibly reduces plasma concentration of levothyroxine </td><td></td></tr><tr><td><a href="41001i900.htm">Oxcarbazepine</a></td><td class="cBV"><b>plasma concentration of  imatinib reduced by oxcarbazepine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i59.htm">Paracetamol</a></td><td>manufacturer of  imatinib advises caution with paracetamol </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b>plasma concentration of  imatinib reduced by phenytoin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>plasma concentration of  imatinib reduced by rifampicin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td> imatinib increases plasma concentration of simvastatin </td><td></td></tr><tr><td><a href="41001i905.htm">St John's Wort</a></td><td class="cBV"><b>plasma concentration of  imatinib reduced by St John's wort—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i222.htm">Warfarin</a></td><td>manufacturer of  imatinib advises replacement of warfarin with a heparin (possibility of enhanced warfarin effect)</td><td></td></tr></tbody></table><p><b>Erlotinib</b> belongs to
      <b>Protein Kinase Inhibitors</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

















<tr><td><a href="41001i110.htm">Antacids</a></td><td class="cBV"><b>plasma concentration of  erlotinib possibly reduced by antacids—give antacids at least 4 hours before or 2 hours after erlotinib</b></td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  erlotinib advised by manufacturer of boceprevir </b></td><td></td></tr><tr><td><a href="41001i923.htm">Capecitabine</a></td><td>plasma concentration of  erlotinib possibly increased by capecitabine </td><td>Capecitabine is a prodrug of fluorouracil</td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td class="cBV"><b>manufacturer of  erlotinib advises avoid concomitant use with cimetidine </b></td><td></td></tr><tr><td><a href="41001i195.htm">Ciprofloxacin</a></td><td>plasma concentration of  erlotinib increased by ciprofloxacin </td><td></td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b>increased risk of bleeding when  erlotinib given with coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i914.htm">Esomeprazole</a></td><td class="cBV"><b>manufacturer of  erlotinib advises avoid concomitant use with esomeprazole </b></td><td></td></tr><tr><td><a href="41001i745.htm">Famotidine</a></td><td class="cBV"><b>manufacturer of  erlotinib advises avoid concomitant use with famotidine </b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td>metabolism of  erlotinib inhibited by ketoconazole (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i753.htm">Lansoprazole</a></td><td class="cBV"><b>manufacturer of  erlotinib advises avoid concomitant use with lansoprazole </b></td><td></td></tr><tr><td><a href="41001i746.htm">Nizatidine</a></td><td class="cBV"><b>manufacturer of  erlotinib advises avoid concomitant use with nizatidine </b></td><td></td></tr><tr><td><a href="41001i60.htm">NSAIDs</a></td><td class="cBV"><b>increased risk of bleeding when  erlotinib given with NSAIDs </b></td><td><i>See also </i>Aspirin. Interactions do not generally apply to topical NSAIDs
</td></tr><tr><td><a href="41001i752.htm">Omeprazole</a></td><td class="cBV"><b>plasma concentration of  erlotinib reduced by omeprazole—manufacturer of erlotinib advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i754.htm">Pantoprazole</a></td><td class="cBV"><b>manufacturer of  erlotinib advises avoid concomitant use with pantoprazole </b></td><td></td></tr><tr><td><a href="41001i869.htm">Rabeprazole</a></td><td class="cBV"><b>manufacturer of  erlotinib advises avoid concomitant use with rabeprazole </b></td><td></td></tr><tr><td><a href="41001i747.htm">Ranitidine</a></td><td class="cBV"><b>plasma concentration of  erlotinib reduced by ranitidine—manufacturer of erlotinib advises give at least 2 hours before or 10 hours after ranitidine</b></td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td>metabolism of  erlotinib accelerated by rifampicin (reduced plasma concentration)</td><td></td></tr></tbody></table><p><b>Dasatinib</b> belongs to
      <b>Protein Kinase Inhibitors</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  dasatinib advised by manufacturer of boceprevir </b></td><td></td></tr><tr><td><a href="41001i745.htm">Famotidine</a></td><td>plasma concentration of  dasatinib possibly reduced by famotidine </td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td>plasma concentration of  dasatinib possibly increased by ketoconazole </td><td></td></tr><tr><td><a href="41001i201.htm">Rifampicin</a></td><td class="cBV"><b>metabolism of  dasatinib accelerated by rifampicin (reduced plasma concentration—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td> dasatinib possibly increases plasma concentration of simvastatin </td><td></td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i1186.htm" title="Pazopanib">Pazopanib</a></li><li><a href="41001i1170.htm" title="Gefitinib">Gefitinib</a></li><li><a href="41001i1169.htm" title="Everolimus">Everolimus</a></li><li><a href="41001i1137.htm" title="Temsirolimus">Temsirolimus</a></li><li><a href="41001i1128.htm" title="Lapatinib">Lapatinib</a></li><li><a href="41001i1118.htm" title="Nilotinib">Nilotinib</a></li><li><a href="41001i1075.htm" title="Sunitinib">Sunitinib</a></li><li><a href="41001i1074.htm" title="Sorafenib">Sorafenib</a></li><li><a href="41001i933.htm" title="Imatinib">Imatinib</a></li><li><a href="41001i1048.htm" title="Erlotinib">Erlotinib</a></li><li><a href="41001i1077.htm" title="Dasatinib">Dasatinib</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i1103.htm">Previous: Trabectedin</a> | <a class="top" href="41001i1087.htm#">Top</a> | <a accesskey="]" href="41001i1186.htm">Next: Pazopanib</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>